Manuscripts and Publications

Filters: Keyword is Forced Expiratory Volume  [Clear All Filters]
2022
O'Toole J, Woo H, Putcha N, Cooper CB, Woodruff P, Kanner RE, Paine R, Bowler RP, Comellas A, Hoth KF et al..  2022.  Comparative Impact of Depressive Symptoms and FEV% on Chronic Obstructive Pulmonary Disease.. Ann Am Thorac Soc. 19(2):171-178.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
2021
Radicioni G, Ceppe A, Ford AA, Alexis NE, R Barr G, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN et al..  2021.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 9(11):1241-1254.
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Oh AL, Mularski RA, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Criner GJ, Han MK, Hansel NN et al..  2021.  Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.. Ann Am Thorac Soc. 18(11):1822-1831.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
2020
Smith BM, Kirby M, Hoffman EA, Kronmal RA, Aaron SD, Allen NB, Bertoni A, Coxson HO, Cooper C, Couper DJ et al..  2020.  Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults.. JAMA. 323(22):2268-2280.
Paulin LM, Gassett AJ, Alexis NE, Kirwa K, Kanner RE, Peters S, Krishnan JA, Paine R, Dransfield M, Woodruff PG et al..  2020.  Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers.. JAMA Intern Med. 180(1):106-115.
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
Zhang WZ, Oromendia C, Kikkers SAnn, Butler JJ, O'Beirne S, Kim K, O'Neal WK, Freeman CM, Christenson SA, Peters SP et al..  2020.  Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.. Sci Rep. 10(1):10562.
2019
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Gu B-H, Choi JC, Shen YH, Song L-Z, Scheurer ME, Luong A, Rodriguez A, Woodruff P, Koth L, Corry DB et al..  2019.  Elastin-Specific Autoimmunity in Smokers With Thoracic Aortic Aneurysm and Dissection is Independent of Chronic Obstructive Pulmonary Disease.. J Am Heart Assoc. 8(8):e011671.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, Lee CHyun, R Barr G, Bleecker E, Cooper CB et al..  2019.  Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS).. Respir Res. 20(1):153.
Arjomandi M, Zeng S, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB et al..  2019.  Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.. Eur Respir J. 54(4)
J Wells M, Arenberg DA, Barjaktarevic I, Bhatt SP, Bowler RP, Christenson SA, Couper DJ, Dransfield MT, Han MK, Hoffman EA et al..  2019.  Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy.. Ann Am Thorac Soc. 16(4):439-446.
Bin Cho H, Chae KJu, Jin GYong, Choi J, Lin CLong, Hoffman EA, Wenzel SE, Castro M, Fain SB, Jarjour NN et al..  2019.  Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers.. Korean J Radiol. 20(7):1236-1245.
2018
Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, J Wells M, Labaki WW, Doerschuk CM et al..  2018.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS.. Ann Am Thorac Soc. 15(6):710-717.
Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I et al..  2018.  Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.. Respir Res. 19(1):223.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, R Barr G, Bleecker E, Cooper CB, Couper D et al..  2018.  Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Respir Res. 19(1):178.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Paulin LM, Smith BM, Koch A, Han ML, Hoffman EA, Martinez C, Ejike C, Blanc PD, Rous J, R Barr G et al..  2018.  Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(12):1411-1419.

Pages